Daniel Auclair, PhD
Therapy for patients with multiple myeloma (MM) encompasses many agents and potential combinations, but truly personalizing care will require knowing how those agents interact for maximum efficacy and incorporating patient preferences for toxicity into the care plan, Daniel Auclair, PhD, explained at the 23rd Annual
International Congress on Hematologic Malignancies®
CoMMpass provides that opportunity, now that it has employed many agents. The most common drugs in the study include dexamethasone, used by close to 100% of patients (n = 1105), followed by lenalidomide (n = 921), bortezomib (n = 865), cyclophosphamide (n = 565), melphalan (n = 527), carfilzomib (n = 417), pomalidomide (Pomalyst; n = 158), daratumumab (n = 139), and prednisone (n = 91), followed by more than 50 other agents with lesser degrees of usage.
Figure. CoMMpass (NCT01454297) in Multiple Myeloma
Many patients benefit from current therapies in MM, but 20% relapse or die within 2 years, according to Auclair. CoMMpass findings may improve upon that statistic. Using whole genome sequencing, investigators analyzed the translocation landscape of 826 patients with newly diagnosed MM.
... to read the full story